<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1208245754
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OCREVUS 30 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OCRELIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20981.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Roche Diagnostics GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Roche Diagnostics GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            F.Hoffmann-La Roche Ltd. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Serious Side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Ocrevus can cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infusion reactions</strong>: Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized.&nbsp; You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms:&nbsp;&nbsp;</p><p>&nbsp;</p><p>o&nbsp;&nbsp; itchy skin</p><p>o&nbsp;&nbsp; rash</p><p>o&nbsp;&nbsp; hives</p><p>o&nbsp;&nbsp; tiredness</p><p>o&nbsp;&nbsp; coughing or wheezing</p><p>o&nbsp;&nbsp; trouble breathing</p><p>o&nbsp;&nbsp; throat irritation or pain</p><p>o&nbsp;&nbsp; feeling faint</p><p>o&nbsp;&nbsp; fever</p><p>o&nbsp;&nbsp; redness on your face (flushing)</p><p>o&nbsp;&nbsp; nausea</p><p>o&nbsp;&nbsp; headache</p><p>o&nbsp;&nbsp; swelling of the throat</p><p>o&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp; shortness of breath</p><p>o&nbsp;&nbsp; fatigue</p><p>o&nbsp;&nbsp; fast heart beat</p><p><strong>These infusion reactions can happen for up to 24 hours after your infusion</strong>.&nbsp; It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion.</p><p>If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infection:</strong> OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Infections are a common side effect, which can be serious<strong>.</strong> Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away. Signs of herpes infection include:</p><p>o&nbsp;&nbsp; cold sores</p><p>o&nbsp;&nbsp; shingles</p><p>o&nbsp;&nbsp; genital sores</p><p>o&nbsp;&nbsp; skin rash</p><p>o&nbsp;&nbsp; pain</p><p>o&nbsp;&nbsp; itching</p><p>&nbsp;</p><p>Signs of a more serious herpes infection include:</p><p>o&nbsp;&nbsp; changes in vision</p><p>o&nbsp;&nbsp; eye redness or eye pain</p><p>o&nbsp;&nbsp; severe or persistent headache</p><p>o&nbsp;&nbsp; stiff neck</p><p>o&nbsp;&nbsp; confusion</p><p>&nbsp;</p><p>Signs of infection can happen during treatment or after you have received your last dose of OCREVUS. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS until your infection is gone.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Progressive Multifocal</strong><strong> Leukoencephalopathy (PML): </strong>Although no cases have been seen with OCREVUS treatment in clinical trials, PML may happen with Ocrevus.&nbsp; PML is a rare brain infection that usually leads to death or severe disability.&nbsp; Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.&nbsp; These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatitis B virus (HBV) reactivation</strong>: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection.&nbsp; If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with Ocrevus.&nbsp; Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death.&nbsp; Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving Ocrevus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Weakened immune system</strong>: Ocrevus taken before or after other medicines that weaken the immune system could increase your risk of getting infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Decreased immunoglobulins: </strong>OCREVUS may cause a decrease in some types of immunoglobulins. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.</p><p><strong>&nbsp;</strong></p><p>See &ldquo;possible side effects of OCREVUS?&rdquo; for more information about side effects.</p><p><strong>&nbsp;</strong></p><p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What </strong><strong>Ocrevus</strong><strong> is and what it is used for</strong></p><p><strong>&nbsp;</strong></p><p><strong>What </strong><strong>Ocrevus</strong><strong> is</strong></p><p><strong>&nbsp;</strong></p><p>Ocrevus contains the active substance &lsquo;ocrelizumab&rsquo;. It is a type of protein called a &lsquo;monoclonal antibody&rsquo;. Antibodies work by attaching to specific targets in your body.</p><p>&nbsp;</p><p><strong>What </strong><strong>Ocrevus</strong><strong> is used for</strong></p><p><strong>&nbsp;</strong></p><p>Ocrevus is a prescription medicine used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relapsing forms of multiple sclerosis (MS),&nbsp;to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary progressive MS, in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given </strong><strong>Ocrevus:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an active hepatitis B virus (HBV) infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a life threatening allergic reaction to OCREVUS.&nbsp; Tell your healthcare provider if you have had an allergic reaction to Ocrevus or any of its ingredients in the past.&nbsp; See &ldquo;What are the ingredients in Ocrevus?&rdquo; for a complete list of ingredients in Ocrevus.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p><strong>&nbsp;</strong></p><p><strong>Before receiving Ocrevus, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or think you have an infection.&nbsp; See <strong>&ldquo;Serious side effects&rdquo;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS.&nbsp; These medicines could increase your risk of getting an infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had hepatitis B or are a carrier of the hepatitis B virus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a recent vaccination or are scheduled to receive any vaccinations.&nbsp;</p><p>o&nbsp;&nbsp; <strong>You should receive any required &lsquo;live&rsquo; or &lsquo;live-attenuated&rsquo; vaccines at least 4 weeks before you start treatment with </strong>Ocrevus<strong>.&nbsp; </strong>You <strong>should not receive </strong>&lsquo;live&rsquo; or &lsquo;live-attenuated&rsquo; vaccines while you are being treated with Ocrevus and until your healthcare provider tells you that your immune system is no longer weakened.</p><p>o&nbsp;&nbsp; <strong>When possible, you should receive any &lsquo;non-live&rsquo; vaccines at least 2 weeks before you start treatment with </strong>Ocrevus<strong>.</strong>&nbsp; If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with Ocrevus, talk to your healthcare provider.</p><p>o&nbsp;&nbsp;&nbsp; If you have a baby and you received OCREVUS during your pregnancy, it is important to tell your baby&rsquo;s healthcare provider about receiving OCREVUS so they can decide when your baby should be vaccinated.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>It is not known if Ocrevus is safe and effective in children.</p><p><strong>Other medicines and </strong><strong>Ocrevus</strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>In particular tell your doctor if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever taken, are taking or are planning to take <strong>medicines that affect the immune system </strong>&ndash; such as chemotherapy, immunosuppressants or other medicines used to treat MS. The effect on the immune system of these medicines with Ocrevus could be too strong.&nbsp; Your doctor may decide to delay your treatment with Ocrevus or may ask you to stop such medicines before starting treatment with Ocrevus.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before you are given Ocrevus.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and Breast-feeding</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or planning to become pregnant talk to your doctor about vaccinations for your baby, as some precautions may be needed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think that you might be pregnant, or plan to become pregnant.&nbsp; It is not known if Ocrevus will harm your unborn baby.&nbsp; You should use birth control (contraception) during treatment with OCREVUS and for 6&nbsp;months after your last infusion of Ocrevus. Talk with your healthcare provider about what birth control method is right for you during this time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breastfeeding or plan to breastfeed.&nbsp; It is not known if Ocrevus passes into your breast milk.&nbsp; Talk to your healthcare provider about the best way to feed your baby if you take Ocrevus.</p><p>o&nbsp;&nbsp; <strong>Tell your healthcare provider about all the medicines you take,</strong> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>It is not known whether Ocrevus can affect your being able to drive or use tools or machines.</p><p>Your doctor will tell you whether your MS may affect your ability to drive or use tools and machines safely.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ocrevus is given through a needle placed in your vein (intravenous infusion) in your arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before treatment with Ocrevus, your healthcare provider will give you a corticosteroid medicine and an antihistamine to help reduce infusion reactions (make them less frequent and less severe).&nbsp; You may also receive other medicines to help reduce infusion reactions.&nbsp; See <strong>&ldquo;Serious side effects.&rdquo;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your first full dose of Ocrevus will be given as 2 separate infusions, 2 weeks apart.&nbsp; Each infusion will last about 2 hours and 30 minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your next doses of OCREVUS will be given as 1 infusion every 6 months. These infusions will last about 2 hours to 3 hours and 30 minutes depending on the infusion rate prescribed by your healthcare provider.</p><p><strong>&nbsp;</strong></p><p><strong>If you miss an infusion of Ocrevus</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss an infusion of Ocrevus, talk to your doctor to arrange to have it as soon as possible. Do not wait until your next planned infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To get the full benefit of Ocrevus, it is important that you receive each infusion when it is due.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following side effects have been reported with Ocrevus:</p><p>&nbsp;</p><p><strong>Ocrevus may cause serious side effects, including: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See &ldquo;<strong>Serious side effects&rdquo;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Risk of cancers (malignancies) including breast cancer.</strong>&nbsp; Follow your healthcare provider&rsquo;s instructions about standard screening guidelines for breast cancer.</p><p>Most common side effects include infusion reactions and infections.&nbsp; See &ldquo;<strong>Serious side effects</strong></p><p>These are not all the possible side effects of <strong>Ocrevus</strong>.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ocrevus will be stored by the healthcare professionals at the hospital or clinic under the following conditions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine is to be kept out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine is not to be used after the expiry date which is stated on the outer carton and the vial label after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine is to be stored in a refrigerator (2<sup>o</sup>C - 8<sup>o</sup>C). It is not to be frozen or shaken.The vials are to be kept in the outer carton to protect them from light.&nbsp;</p><p>&nbsp;</p><p>Ocrevus must be diluted before it is given to you. Dilution will be done by a healthcare professional. It is recommended that the product is used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the healthcare professional and would normally not be longer than 24 hours at 2&deg;C - 8&deg;C and subsequently 8 hours at room temperature.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is ocrelizumab. Each vial contains 300 mg of ocrelizumab in 10 mL at a concentration of 30mg/mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium acetate trihydrate, glacial acetic acid, trehalose dihydrate, polysorbate 20.</p><p>&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Ocrevus is a clear to slightly opalescent, and colourless to pale brown solution. 
•	It is supplied as a concentrate for solution for infusion.
•	This medicine is available in packs containing 1 or 2 vials (vials of 10 mL concentrate). Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,&nbsp;</strong></p><p dir="ltr"><strong>CH-4070 Basel,&nbsp;</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2021

To report any side effect(s):
Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
SFDA call center: 19999 
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

Other GCC States:
Please contact the relevant competent authority.

Council of Arab Health Ministers:
This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. 
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
The doctor and the pharmacist are the experts in medicines, their benefits and risks. 
Do not by yourself interrupt the period of treatment prescribed for you. 
Do not repeat the same prescription without consulting your doctor. 
Keep all medicaments out of reach of children. 
Council of Arab Health Ministers
Union of Arab Pharmacists

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>آثار جانبية خطيرة:</strong></p><p dir="RTL">&nbsp;&nbsp; <strong>- يمكن أن يسبب اوكريفوس آثارًا جانبية خطيرة، بما في ذلك:</strong></p><p dir="RTL">&bull; <strong>تفاعلات الحقن</strong>: تفاعلات <strong>الحقن</strong> هي أحد الأعراض الجانبية الشائعة لدواء <strong>أوكريفوس</strong> والتي يمكن أن تكون خطيرة وقد تتطلب دخولك إلى المستشفى. ستتم مراقبتك أثناء الحقن ولمدة ساعة على الأقل بعد كل حقن من <strong>اوكريفوس</strong> بحثًا عن علامات وأعراض تفاعل الحقن. أخبر مقدم الرعاية الصحية أو الممرضة إذا ظهرت عليك أي من هذه الأعراض:</p><p dir="RTL">* حكة في الجلد</p><p dir="RTL">* طفح جلدي</p><p dir="RTL">* القشعريرة</p><p dir="RTL">* التعب</p><p dir="RTL">* السعال أو الصفير</p><p dir="RTL">* صعوبة في التنفس</p><p dir="RTL">* تهيج الحلق أو الألم</p><p dir="RTL">* الشعور بالإغماء</p><p dir="RTL">* الحمى / السخونة</p><p dir="RTL">* احمرار على وجهك (<strong>احمرار</strong>)</p><p dir="RTL">* الغثيان</p><p dir="RTL">* الصداع</p><p dir="RTL">* انتفاخ في الحلق</p><p dir="RTL">* الدوار</p><p dir="RTL">* ضيق في التنفس</p><p dir="RTL">* الشعور بالتعب والارهاق</p><p dir="RTL">* سرعة ضربات القلب</p><p dir="RTL">يمكن أن تحدث تفاعلات <strong>الحقن</strong> هذه لمدة تصل إلى أربعة وعشرون (24) ساعة بعد <strong>الحقن</strong>. من المهم أن تتصل بمقدم الرعاية الصحية الخاص بك على الفور إذا ظهرت عليك أي من العلامات أو الأعراض المذكورة أعلاه بعد كل عملية حقن.</p><p dir="RTL">إذا حصلت على تفاعلات <strong>الحقن</strong>، فقد يحتاج مقدم الرعاية الصحية الخاص بك إلى إيقاف أو إبطاء معدل <strong>الحقن</strong>.</p><p dir="RTL"><strong>&bull; الالتهابات:</strong></p><p>* يزيد <strong>اوكريفوس </strong>من خطر الإصابة بعدوى الجهاز التنفسي العلوي والتهابات الجهاز التنفسي السفلي والتهابات الجلد والتهابات الهربس. تعد العدوى من الآثار الجانبية الشائعة ، والتي يمكن أن تكون خطيرة. أخبر مقدم الرعاية الصحية الخاص بك إذا كنت تعاني من عدوى أو لديك أي من علامات العدوى التالية بما في ذلك الحمى أو القشعريرة أو السعال الذي لا يختفي. تشمل علامات عدوى الهربس:</p><p>* قروح البرد</p><p>* القوباء المنطقية</p><p>* تقرحات الأعضاء التناسلية</p><p>* حساسية جلدية</p><p>* حكة في الجلد</p><p>* ألم</p><p>&nbsp;</p><p>&nbsp;</p><p>أما علامات عدوى الهربس الأكثر خطورة فتشمل:</p><p>* تغير في الرؤية</p><p>* احمرار العين، أو ألم في العين</p><p>* صداع شديد أو مستمر</p><p>* الارتباك</p><p>* تصلب الرقبة</p><p>يمكن أن تحدث هذه العلامات أثناء العلاج أو بعد تلقي آخر جرعة من <strong>اوكريفوس</strong>. تحدث مع مقدم الرعاية الصحية فور اصابتك بأي عدوى. يجب على مقدم الرعاية الصحية الخاص بك تأخير علاجك مع <strong>اوكريفوس </strong>حتى تختفي العدوى.</p><p dir="RTL"><strong>* اعتلال بيضاء الدماغ متعدد البؤر التقدمي (مرض المادة البيضاء): </strong>على الرغم من عدم وجود حالات مع علاج <strong>اوكريفوس </strong>في التجارب السريرية، فقد يحدث <strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي (مرض المادة البيضاء)</strong> مع <strong>اوكريفوس</strong>. <strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي (مرض المادة البيضاء)</strong> هو عدوى دماغية نادرة تؤدي عادةً إلى الوفاة أو الإعاقة الشديدة. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا كان لديك أي علامات أو أعراض عصبية جديدة أو تزداد سوءًا. قد تشمل هذه المشاكل في التفكير، والتوازن، والبصر، والضعف في جانب واحد من جسمك، والقوة، أو استخدام ذراعيك أو ساقيك.</p><p dir="RTL"><strong>* إعادة تنشيط فيروس التهاب الكبد (ب):</strong> قبل بدء العلاج باستخدام <strong>اوكريفوس</strong>، سيقوم مقدم الرعاية الصحية الخاص بك بإجراء فحوصات الدم للتحقق من وجود عدوى فيروسية بالتهاب الكبد <strong>(ب)</strong>. إذا كنت قد أصبت في أي وقت مضى بعدوى فيروس التهاب الكبد <strong>(ب)</strong>، فقد ينشط فيروس التهاب الكبد <strong>(ب)</strong> مرة أخرى أثناء أو بعد العلاج باستخدام <strong>اوكريفوس</strong>. قد يؤدي تنشيط فيروس التهاب الكبد <strong>(ب)</strong> مرة أخرى (<strong>يسمى إعادة التنشيط</strong>) إلى مشاكل خطيرة في الكبد بما في ذلك فشل الكبد أو الوفاة. سيراقبك مقدم الرعاية الصحية الخاص بك إذا كنت معرضًا لخطر إعادة تنشيط فيروس التهاب الكبد <strong>(ب)</strong> أثناء العلاج وبعد التوقف عن تلقي <strong>اوكريفوس</strong>.&nbsp;&nbsp;</p><p dir="RTL"><strong>* ضعف جهاز المناعة:</strong> قد يؤدي تناول عقار <strong>اوكريفوس</strong> قبل أو بعد الأدوية الأخرى التي تضعف جهاز المناعة إلى زيادة خطر الإصابة بالعدوى.</p><p dir="RTL"><strong>* انخفاض الغلوبولين المناعي: </strong>قد يسبب <strong>اوكريفوس</strong> انخفاضًا في بعض الغلوبولين. سيقوم مقدم الرعاية الصحية الخاص بك بإجراء فحوصات الدم للتحقق من مستويات الغلوبولين المناعي في الدم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">انظر <strong>&quot;الآثار الجانبية المحتملة</strong>&quot; لمعلومات أكثر حول الأعراض الجانبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>(2) ما هو دواء اوكريفوس وما هو استخدامه.</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; - ما هو</strong> <strong>عقار</strong> <strong>اوكريفوس</strong>.</p><p dir="RTL">يحتوي <strong>عقار</strong> <strong>اوكريفوس</strong> على المادة الفعالة &quot;<strong>أوكرليزوماب</strong>&quot;. وهو نوع من البروتين يسمى <strong>&quot;الأجسام المضادة أحادية النسيلة&quot;</strong>. تعمل الأجسام المضادة من خلال الارتباط بأهداف محددة في جسمك.</p><p dir="RTL"><strong>&nbsp;&nbsp; - لماذا يستخدم عقار اوكريفوس. </strong></p><p dir="RTL"><strong>&nbsp; عقار</strong> <strong>اوكريفوس</strong> <strong>هو دواء وصفة طبية يستخدم لعلاج:</strong></p><p dir="RTL">&bull; أشكال الانتكاس من التصلب المتعدد، لتشمل المتلازمة المعزولة سريريًا، ومرض الانتكاس المتحول، والمرض التدريجي الثانوي النشط، لدى البالغين</p><p dir="RTL">&bull; التصلب اللويحي التدريجي الأولي عند البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا تحصل على <strong>عقار</strong> <strong>اوكريفوس</strong>:</p><p dir="RTL">* إذا كنت مصابًا بعدوى نشطة بفيروس <strong>التهاب الكبد (ب).</strong></p><p dir="RTL">* إذا كان لديك رد فعل تحسسي يهدد الحياة تجاه <strong>عقار</strong> <strong>اوكريفوس</strong>. أخبر مقدم الرعاية الصحية الخاص بك إذا كان لديك رد فعل تحسسي تجاه <strong>عقار</strong> <strong>اوكريفوس</strong> أو أي من مكوناته في الماضي. راجع <strong>&quot;ما هي المكونات الموجودة في عقار اوكريفوس؟&quot;</strong> للحصول على قائمة كاملة بالمكونات في <strong>عقار</strong> <strong>اوكريفوس</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>* المحاذير والاحتياطات</strong></p><p dir="RTL">قبل تلقي <strong>عقار</strong> <strong>اوكريفوس</strong>، أخبر مقدم الرعاية الصحية الخاص بك عن جميع حالاتك الطبية، <strong>بما في ذلك إذا كنت:</strong></p><p dir="RTL">&bull; لديك أو تعتقد أنك مصاب بالتهاب. انظر <strong>&quot;الآثار الجانبية الخطيرة&quot;</strong>.</p><p dir="RTL">&bull; سبق لك أن تناولت أو تناولت أو خططت لتناول أدوية تؤثر على جهاز المناعة لديك أو علاجات أخرى لمرض التصلب العصبي المتعدد. يمكن أن تزيد هذه الأدوية من خطر الإصابة بالتهاب.</p><p dir="RTL">&bull; سبق أن أصبت <strong>بالتهاب الكبد (ب)</strong> أو كانت حاملاً لفيروس <strong>التهاب الكبد (ب)</strong>.</p><p dir="RTL">&bull; تلقيت تطعيمًا مؤخرًا أو من المقرر أن تتلقى أي تطعيمات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتلقى أي لقاحات <strong>&quot;حية&quot;</strong> أو <strong>&quot;</strong><strong>لقاح حي موهن / اللَّقاح الموَهَّن</strong><strong>&quot;</strong> مطلوبة قبل أربعة (4) أسابيع على الأقل من بدء العلاج مع <strong>عقار</strong> <strong>اوكريفوس</strong>. يجب ألا تتلقى لقاحات &quot;حية&quot; أو &quot;حية موهنه&quot; أثناء علاجك <strong>بعقار</strong> <strong>اوكريفوس</strong> وحتى يخبرك مقدم الرعاية الصحية أن نظام المناعة لديك لم يعد ضعيفًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند الإمكان، يجب أن تتلقى أي لقاحات <strong>&quot;غير حية&quot;</strong> قبل أسبوعين على الأقل من بدء العلاج مع <strong>عقار</strong> <strong>اوكريفوس</strong>. إذا كنت ترغب في تلقي أي لقاحات غير حية <strong>(غير نشطة)</strong>، بما في ذلك لقاح الأنفلونزا الموسمية، أثناء علاجك <strong>بعقار</strong> <strong>اوكريفوس</strong>، تحدث إلى مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك طفل وتلقيت<strong> عقار</strong> <strong>اوكريفوس </strong>أثناء الحمل ، فمن المهم إخبار مقدم الرعاية الصحية الخاص بطفلك حتى يتمكنوا من تحديد موعد تطعيم طفلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>* الأطفال واليافعين </strong></p><p dir="RTL">من غير المعروف ما إذا كان <strong>عقار</strong> <strong>اوكريفوس</strong> آمنًا و فعالًا عند الأطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>* الأدوية الأخرى وعقار</strong> <strong>اوكريفوس</strong></p><p dir="RTL">&nbsp;&nbsp; - أخبر طبيبك إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;&nbsp; - أخبر طبيبك بشكل خاص إذا:</strong></p><p dir="RTL">&bull; تناولت في أي وقت مضى أدوية تؤثر على جهاز المناعة أو تتناولها أو تخطط لتناولها - مثل العلاج الكيميائي أو مثبطات المناعة أو الأدوية الأخرى المستخدمة لعلاج مرض التصلب العصبي المتعدد. قد يكون التأثير على الجهاز المناعي لهذه الأدوية مع <strong>عقار</strong> <strong>اوكريفوس</strong> قويًا جدًا. قد يقرر طبيبك تأجيل علاجك <strong>بعقار</strong> <strong>اوكريفوس</strong> أو قد يطلب منك إيقاف هذه الأدوية قبل بدء العلاج <strong>بعقار</strong> <strong>اوكريفوس</strong>.</p><p dir="RTL">&bull; إذا كان أي مما سبق ينطبق عليك <strong>(أو لم تكن متأكدًا)</strong>، تحدث إلى طبيبك قبل أن تحصل على <strong>عقار</strong> <strong>اوكريفوس</strong>.</p><p dir="RTL"><strong>* الحمل والرضاعة الطبيعية</strong>&nbsp;</p><p dir="RTL">&bull; إذا كنت حاملاً أو تخططين للحمل تحدثي إلى طبيبك بشأن التطعيمات لطفلك، حيث قد تكون هناك حاجة لبعض الاحتياطات.</p><p dir="RTL">&bull; إذا كنت حاملاً، تعتقدين أنك حامل، أو تخططين للحمل. من غير المعروف ما إذا كان ع<strong> عقار</strong> <strong>اوكريفوس</strong> سيؤذي طفلك الذي لم يولد بعد. يجب عليك استخدام وسائل منع الحمل أثناء العلاج <strong>بعقار</strong> <strong>اوكريفوس</strong> ولمدة (6) ستة أشهر بعد آخر حقن <strong>بعقار</strong> <strong>اوكريفوس</strong>. تحدث إلى مقدم الرعاية الصحية الخاص بك حول أنسب وسيلة منع حمل خلال فترة تعاطي <strong>اوكريفوس.</strong></p><p dir="RTL">&bull; إذا كنت ترضعين طفلك أو تخططين للإرضاع. من غير المعروف ما إذا كان <strong>عقار</strong> <strong>اوكريفوس</strong> يمر في حليب الثدي الخاص بك. تحدث إلى مقدم الرعاية الصحية الخاص بك حول أفضل طريقة لإطعام طفلك إذا كنت تتناول <strong>عقار</strong> <strong>اوكريفوس</strong>.</p><p dir="RTL">&bull; أخبر مقدم الرعاية الصحية الخاص بك عن جميع الأدوية التي تتناولها، بما في ذلك الأدوية التي تصرف دون وصفة طبية والفيتامينات والمكملات العشبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>* القيادة واستعمال الماكينات</strong></p><p dir="RTL">من غير المعروف ما إذا كان <strong>عقار</strong> <strong>اوكريفوس</strong> يمكن أن يؤثر على قدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p dir="RTL">سيخبرك طبيبك ما إذا كان مرض التصلب العصبي المتعدد لديك قد يؤثر على قدرتك على القيادة أو استخدام الأدوات والآلات بأمان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يتم إعطاء <strong>عقار</strong> <strong>اوكريفوس</strong> من خلال إبرة موضوعة في وريدك <strong>(الحقن في الوريد)</strong> في ذراعك.</p><p dir="RTL">&bull; قبل العلاج <strong>بعقار</strong> <strong>اوكريفوس</strong>، سوف يعطيك مقدم الرعاية الصحية دواء كورتيكوستيرويد ومضاد للهستامين للمساعدة في تقليل تفاعلات الحقن (<strong>تجعلها أقل تكرارا وأقل شدة)</strong>. قد تتلقى أيضًا أدوية أخرى للمساعدة في تقليل تفاعلات الحقن. انظر <strong>&quot;الآثار الجانبية الخطيرة&quot;.</strong></p><p dir="RTL">&bull; سيتم إعطاؤك أول جرعة كاملة من <strong>عقار</strong> <strong>اوكريفوس</strong> على شكل دفعتين منفصلتين، كل أسبوعين على حدة. سيستمر كل حقن حوالي ساعتين وثلاثون (30) دقيقة.</p><p dir="RTL">- سيتم إعطاء جرعاتك التالية من <strong>عقار</strong> <strong>اوكريفوس</strong> في شكل حقن مرة واحدة كل ستة (6) أشهر. سوف تستمر هذه عملية الحقن حوالي ساعتين (2) إلى ثلاث (3) ساعات وثلاثون (30). معتمدة على معدل الحقن الذي يصفه الطبيب المعالج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>* إذا فاتتك جرعة من عقار اوكريفوس</strong></p><p dir="RTL">&bull; إذا فاتتك جرعة من ع<strong> عقار</strong> <strong>اوكريفوس</strong>، تحدث إلى طبيبك لترتيب الحصول عليه في أقرب وقت ممكن. لا تنتظر حتى موعد الحقن التالي المخطط له.</p><p dir="RTL">&bull; للحصول على الفائدة الكاملة من <strong>عقار</strong> <strong>اوكريفوس</strong>، من المهم أن تتلقى كل حقنة عندما يحين موعدها.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp; - مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;&nbsp; <strong>- لقد تم الإبلاغ عن الآثار الجانبية التالية مع عقار</strong> <strong>اوكريفوس</strong>:</p><p dir="RTL"><strong>قد يسبب عقار اوكريفوس آثارًا جانبية خطيرة، بما في ذلك: </strong></p><p dir="RTL"><strong>&bull; انظر &quot;الآثار الجانبية الخطيرة&quot;.</strong></p><p dir="RTL">&bull; قد تحدث زيادة في نسبة الإصابة بالأورام الخبيثة بما في ذلك سرطان الثدي. اتبعي تعليمات مقدم الرعاية الصحية الخاص بك حول إرشادات الفحص القياسية لسرطان الثدي.</p><p dir="RTL">هذه ليست كل الآثار الجانبية المحتملة <strong>لعقار اوكريفوس</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>* التبليغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;&nbsp; إذا عانيت من أي آثار جانبية، تحدث إلى طبيبك أو ممرضتك. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سيتم تخزين عقار اوكريفوس من قبل المتخصصين في الرعاية الصحية في المستشفى أو العيادة وفقًا للشروط التالية:</strong></p><p dir="RTL">&bull; يحفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">&bull; لا يستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية الخارجية وعلامة القارورة بعد <strong>&quot;انتهاء الصلاحية&quot;</strong>. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&bull; يتم تخزين هذا الدواء في الثلاجة <strong>(2 درجة مئوية - 8 درجة مئوية)</strong>. لا يتم تجميدها أو رجها، ويجب حفظ القوارير في الكرتون الخارجي لحمايتها من الضوء.</p><p dir="RTL">يجب تخفيف <strong>عقار</strong> <strong>اوكريفوس</strong> قبل إعطائه لك. سيتم إجراء التخفيف بواسطة أخصائي رعاية صحية. يوصى باستخدام المنتج مباشرة بعد التخفيف. إذا لم يتم استخدامه على الفور، فإن أوقات التخزين أثناء الاستخدام وظروفه قبل الاستخدام تقع على عاتق أخصائي الرعاية الصحية ولن تزيد في العادة عن <strong>أربعة وعشرون (24) ساعة</strong> عند <strong>(2 درجة مئوية - 8 درجات مئوية) </strong>وبعد ذلك <strong>بثمانية (8) ساعات</strong> في درجة حرارة الغرفة.</p><p dir="RTL">لا يجوز رمي الأدوية في مياه الصرف الصحي. <strong>من شأن (مثل)</strong> هذه التدابير أن تساعد على حماية البيئة.&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة هي <strong>أوكرليزوماب</strong>. تحتوي كل قنينة على ثلاثمائة (300) مجم من <strong>أوكرليزوماب</strong> في (10) مل بتركيز (30) مجم / مل.</p><p dir="RTL">&bull; المكونات الأخرى هي أسيتات الصوديوم ثلاثي الهيدرات، وحمض الخليك الجليدي، وثنائي هيدرات تريهالوز، وبولي سوربات (20).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; <strong>عقار</strong> <strong>اوكريفوس</strong> هو محلول صافٍ إلى براق قليلاً، وعديم اللون إلى البني الشاحب.</p><p dir="RTL">&bull; يتم توفيره كمركز لمحلول التسريب.</p><p dir="RTL">&bull; يتوفر هذا الدواء في عبوات تحتوي على <strong>(1) أو (2)</strong> قنينة <strong>(قوارير من &quot;10&quot; مل مركز)</strong>. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شركة ف. هوفمان لا روش المحدودة</strong></p><p dir="rtl"><strong>142 جرينزاهاشتراس</strong></p><p dir="rtl"><strong>CH-4070 بازل</strong></p><p dir="rtl"><strong>سويسرا</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في تاريخ مارس 2021.

للإبلاغ عن الآثار الجانبية:

المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
فاكس: 7662-205-11-966+
مركز الاتصال الموحد للهيئة العامة للغذاء والدواء 1999
بريد الكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: www.sfda.gov.sa

دول مجلس التعاون الخليجي الأخرى:
يرجى التواصل مع الهيئة المعنية ذات الصلة.

مجلس وزارات الصحة العربية
هذا المنتج دوائي
قد تؤثر المنتجات الدوائية على صحتك، ويعد استهلاكه بخلاف الطريقة المحددة أمرًا خطيرًا.
اتبع وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء بدقة.
الطبيب والصيدلي خبراء في المنتجات الدوائية وفوائدها ومخاطرها.
لا تقطع فترة العلاج المحددة لك من تلقاء نفسك.
لا تكرر استخدام نفس الوصفة الطبية دون استشارة طبيبك.
احتفظ بجميع المنتجات الدوائية بعيدًا عن متناول الأطفال.






مجلس وزارات الصحة العربية
اتحاد الصيادلة العرب


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ocrevus 300 mg concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells. Ocrelizumab is a glycosylated immunoglobulin G1 (IgG1) with a molecular mass of approximately 145 kDa.
OCREVUS (ocrelizumab) Injection for intravenous infusion is a preservative-free, sterile, clear or slightly opalescent, and colorless to pale brown solution supplied in single-dose vials.  Each mL of solution contains 30 mg ocrelizumab, glacial acetic acid (0.25 mg), polysorbate 20 (0.2 mg), sodium acetate trihydrate (2.14 mg), and trehalose dihydrate (40 mg) at pH 5.3.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion
Injection: 300 mg/10 mL (30 mg/mL) clear or slightly opalescent, and colorless to pale brown solution in a single-dose vial.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OCREVUS is indicated for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary progressive MS, in adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Assessments Prior to First Dose of OCREVUS </strong></p><p><u>Hepatitis B Virus Screening</u></p><p>Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening.&nbsp; OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBV tests.&nbsp; For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment <em>[see 4.4 Special warnings and precautions for use]</em>.</p><p>&nbsp;</p><p><u>Serum Immunoglobulins</u></p><p>Prior to initiating OCREVUS, perform testing for quantitative serum immunoglobulins <em>[see 4.4 Special warnings and precautions for use]</em>. For patients with low serum immunoglobulins, consult immunology experts before initiating treatment with OCREVUS.</p><p><u>&nbsp;</u></p><p><u>Vaccinations</u></p><p>Because vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation until B-cell repletion, administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of OCREVUS for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of OCREVUS for non-live vaccines <em>[see 4.4 Special warnings and precautions for use and 5.1 </em><em>Pharmacodynamic Properties</em><em>]</em>.</p><p>&nbsp;</p><p>Preparation Before Every Infusion</p><p><u>Infection Assessment</u></p><p>Prior to every infusion of OCREVUS, determine whether there is an active infection.&nbsp; In case of active infection, delay infusion of OCREVUS until the infection resolves <em>[see 4.4 Special warnings and precautions for use].</em></p><p><u>Recommended Premedication</u></p><p>Pre-medicate with 100 mg of methylprednisolone (or an equivalent corticosteroid) administered intravenously approximately 30 minutes prior to each OCREVUS infusion to reduce the frequency and severity of infusion reactions <em>[see</em> <em>4.4 Special warnings and precautions for use]</em>.&nbsp; Pre-medicate with an antihistamine (e.g., diphenhydramine) approximately 30-60 minutes prior to each OCREVUS infusion to further reduce the frequency and severity of infusion reactions.</p><p>The addition of an antipyretic (e.g., acetaminophen) may also be considered.</p><p>Recommended Dosage and Dose Administration &nbsp;</p><p>Administer OCREVUS under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subsequent doses:&nbsp; single 600 mg intravenous infusion every 6 months. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Observe the patient for at least one hour after the completion of the infusion <em>[see </em><em>4.4 Special warnings and precautions for use</em><em>]</em>.</p><p>&nbsp;</p><p><strong>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dose, Infusion Rate, and Infusion Duration for RMS and PPMS </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Amount and Volume<sup>1</sup></strong></p></td><td><p><strong>Infusion Rate and Duration<sup>3</sup></strong></p></td></tr><tr><td rowspan="2"><p><strong>Initial Dose</strong></p><p>(two infusions)</p></td><td><p>Infusion 1</p></td><td><p>300 mg</p><p>in 250 mL</p></td><td rowspan="2"><p>&middot;&nbsp;&nbsp; Start at 30 mL per hour</p><p>&middot;&nbsp;&nbsp; Increase by 30&nbsp;mL per hour every 30 minutes</p><p>&middot;&nbsp;&nbsp; Maximum: 180 mL per hour</p><p>&middot;&nbsp;&nbsp; Duration: 2.5 hours or longer</p></td></tr><tr><td><p>Infusion 2</p><p>(2 weeks later)</p></td><td><p>300 mg</p><p>in 250 mL</p></td></tr><tr><td rowspan="3"><p><strong>Subsequent Doses</strong></p><p>(one infusion)</p><p>every 6 months)<sup>2</sup></p></td><td><p><sup>&nbsp;</sup></p><p>Option 1</p><p><sup>&nbsp;</sup></p><p>Infusion of approximately 3.5 hours duration<sup>3</sup></p><p>&nbsp;</p></td><td><p>600 mg</p><p>in 500 mL</p></td><td><p>&middot;&nbsp;&nbsp; Start at 40 mL per hour</p><p>&middot;&nbsp;&nbsp; Increase by 40&nbsp;mL per hour every 30 minutes</p><p>&middot;&nbsp;&nbsp; Maximum: 200 mL per hour</p><p>&middot;&nbsp;&nbsp; Duration: 3.5 hours or longer</p></td></tr><tr><td colspan="3"><p>OR</p></td></tr><tr><td><p>Option 2&nbsp;</p><p>(If no prior serious infusion reaction with any previous OCREVUS infusion)<sup>4 </sup></p><p>&nbsp;</p><p>Infusion of approximately 2 hours</p><p>duration<sup>3</sup></p></td><td><p>600 mg</p><p>in 500 mL</p></td><td><p>&middot;&nbsp;&nbsp; Start at 100 mL per hour for the first 15 minutes</p><p>&middot;&nbsp;&nbsp; Increase to 200 mL per hour for the next 15 minutes</p><p>&middot;&nbsp;&nbsp; Increase to 250 mL per hour for the next 30 minutes</p><p>&middot;&nbsp;&nbsp; Increase to 300 mL per hour for the remaining 60 minutes</p><p>Duration: 2 hours or longer</p></td></tr></tbody></table><p><sup>1</sup> Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% Sodium Chloride Injection, to a final drug concentration of approximately 1.2 mg/mL.</p><p><sup>2</sup> Administer the first Subsequent Dose 6 months after Infusion 1 of the Initial Dose.</p><p><sup>3</sup> Infusion time may take longer if the infusion is interrupted or slowed <em>[see 4.2 Posology and method of administration]</em>.</p><p><sup>4</sup> <em>[</em><em>see 4.8 Undesirable effects</em><em> and 5.1 </em><em>Pharmacodynamic Properties</em><em>]</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p>Delayed or Missed Doses</p><p>If a planned infusion of OCREVUS is missed, administer OCREVUS as soon as possible; do not wait until the next scheduled dose. &nbsp;Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered.&nbsp; Doses of OCREVUS must be separated by at least 5 months <em>[</em><em>see </em><em>4.2 Posology and method of administration</em><em>]</em>.</p><p>&nbsp;</p><p>Dose Modifications Because of Infusion Reactions</p><p>Dose modifications in response to infusion reactions depends on the severity.&nbsp;</p><p><u>Life-threatening Infusion Reactions </u></p><p>Immediately stop and permanently discontinue OCREVUS if there are signs of a life-threatening or disabling infusion reaction <em>[see 4.4 Special warnings and precautions for use]</em>. &nbsp;Provide appropriate supportive treatment.</p><p><u>&nbsp;</u></p><p><u>Severe </u><u>Infusion Reactions </u></p><p>Immediately interrupt the infusion and administer appropriate supportive treatment, as necessary <em>[see 4.4 Special warnings and precautions for use]</em>. &nbsp;Restart the infusion only after all symptoms have resolved. &nbsp;When restarting, begin at half of the infusion rate at the time of onset of the infusion reaction <em>[see </em><em>4.2 Posology and method of administration]</em>.&nbsp; If this rate is tolerated, increase the rate as described in Table 1.&nbsp; This change in rate will increase the total duration of the infusion but not the total dose.</p><p><u>Mild to Moderate </u><u>Infusion Reactions </u></p><p>Reduce the infusion rate to half the rate at the onset of the infusion reaction and maintain the reduced rate for at least 30 minutes <em>[see 4.4 Special warnings and precautions for use]</em>. &nbsp;If this rate is tolerated, increase the rate as described in Table 1.&nbsp; This change in rate will increase the total duration of the infusion but not the total dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OCREVUS is contraindicated in patients with:
•	Active HBV infection [see 4.2 Posology and method of administration and 4.4 Special warnings and precautions for use]
•	A history of life-threatening infusion reaction to OCREVUS [see 4.4 Special warnings and precautions for use]

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Infusion Reactions</strong></p><p>OCREVUS can cause infusion reactions, which can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis.&nbsp; In multiple sclerosis (MS) clinical trials, the incidence of infusion reactions in OCREVUS-treated patients [who received methylprednisolone (or an equivalent steroid) and possibly other pre-medication to reduce the risk of infusion reactions prior to each infusion] was 34 to 40%, with the highest incidence with the first infusion.&nbsp; There were no fatal infusion reactions, but 0.3% of OCREVUS-treated MS patients experienced infusion reactions that were serious, some requiring hospitalization.</p><p>Observe patients treated with OCREVUS for infusion reactions during the infusion and for at least one hour after completion of the infusion.&nbsp; Inform patients that infusion reactions can occur up to 24 hours after the infusion.</p><p><u>Reducing the Risk of Infusion Reactions and Managing Infusion Reactions </u></p><p>Administer pre-medication (e.g., methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of infusion reactions. &nbsp;The addition of an antipyretic (e.g., acetaminophen) may also be considered <em>[see </em><em>4.2 Posology and method of administration].</em>Management recommendations for infusion reactions depend on the type and severity of the reaction <em>[see </em><em>4.2 Posology and method of administration].</em> &nbsp;For life-threatening infusion reactions, immediately and permanently stop OCREVUS and administer appropriate supportive treatment. &nbsp;For less severe infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Infections</strong></p><p>A higher proportion of OCREVUS-treated patients experienced infections compared to patients taking REBIF or placebo. &nbsp;In RMS trials, 58% of OCREVUS-treated patients experienced one or more infections compared to 52% of REBIF-treated patients.&nbsp; In the PPMS trial, 70% of OCREVUS-treated patients experienced one or more infections compared to 68% of patients on placebo.&nbsp; OCREVUS increased the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections <em>[see 4.8 Undesirable effects].</em> &nbsp;OCREVUS was not associated with an increased risk of serious infections in MS patients. &nbsp;</p><p>Delay OCREVUS administration in patients with an active infection until the infection is resolved.</p><p><u>&nbsp;</u></p><p><u>Respiratory Tract Infections</u></p><p>A higher proportion of OCREVUS-treated patients experienced respiratory tract infections compared to patients taking REBIF or placebo. &nbsp;In RMS trials, 40% of OCREVUS-treated patients experienced upper respiratory tract infections compared to 33% of REBIF-treated patients, and 8% of OCREVUS-treated patients experienced lower respiratory tract infections compared to 5% of REBIF-treated patients.&nbsp; In the PPMS trial, 49% of OCREVUS-treated patients experienced upper respiratory tract infections compared to 43% of patients on placebo and 10% of OCREVUS-treated patients experienced lower respiratory tract infections compared to 9% of patients on placebo.&nbsp; The infections were predominantly mild to moderate and consisted mostly of upper respiratory tract infections and bronchitis.</p><p><u>&nbsp;</u></p><p><u>Herpes</u></p><p>In active-controlled (RMS) clinical trials, herpes infections were reported more frequently in OCREVUS-treated patients than in REBIF-treated patients, including herpes zoster (2.1% vs. 1.0%), herpes simplex (0.7% vs. 0.1%), oral herpes (3.0% vs. 2.2%), genital herpes (0.1% vs. 0%), and herpes virus infection (0.1% vs. 0%). &nbsp;Infections were predominantly mild to moderate in severity.</p><p>In the placebo-controlled (PPMS) clinical trial, oral herpes was reported more frequently in the OCREVUS-treated patients than in the patients on placebo (2.7% vs 0.8%).</p><p>Serious cases of infections caused by herpes simplex virus and varicella zoster virus, including central nervous system infections (encephalitis and meningitis), intraocular infections, and disseminated skin and soft tissue infections, have been reported in the postmarketing setting in multiple sclerosis patients receiving OCREVUS. Serious herpes virus infections may occur at any time during treatment with OCREVUS. Some cases were life-threatening.</p><p>If serious herpes infections occur, OCREVUS should be discontinued or withheld until the infection has resolved, and appropriate treatment should be administered.</p><p><em>&nbsp;</em></p><p><u>Progressive Multifocal Leukoencephalopathy (PML)</u></p><p>PML is an opportunistic viral infection of the brain caused by the John Cunningham (JC) virus that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.&nbsp; Although no cases of PML were identified in OCREVUS clinical trials, JC virus infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies and has been associated with some risk factors (e.g., immunocompromised patients, polytherapy with immunosuppressants). &nbsp;At the first sign or symptom suggestive of PML, withhold OCREVUS and perform an appropriate diagnostic evaluation.&nbsp; MRI findings may be apparent before clinical signs or symptoms.&nbsp; Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.</p><p><u>Hepatitis B Virus (HBV) Reactivation</u></p><p>Hepatitis B reactivation has been reported in MS patients treated with OCREVUS in the postmarketing setting.&nbsp; Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. &nbsp;Perform HBV screening in all patients before initiation of treatment with OCREVUS. Do not administer OCREVUS to patients with active HBV confirmed by positive results for HBsAg and anti-HB tests.&nbsp; For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment.</p><p><u>&nbsp;</u></p><p><u>Possible Increased Risk of Immunosuppressant Effects with Other Immunosuppressants</u></p><p>When initiating OCREVUS after an immunosuppressive therapy or initiating an immunosuppressive therapy after OCREVUS, consider the potential for increased immunosuppressive effects <em>[see </em><em>4.5 Interaction with other medicinal products and other forms of interaction</em><em> and 5.1 </em><em>Pharmacodynamic Properties</em><em>].</em> OCREVUS has not been studied in combination with other MS therapies.</p><p><u>&nbsp;</u></p><p><u>Vaccinations </u></p><p>Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of OCREVUS for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of OCREVUS for non-live vaccines.</p><p>OCREVUS may interfere with the effectiveness of non-live vaccines <em>[see </em><em>4.5 Interaction with other medicinal products and other forms of interaction</em><em>]</em><em>.</em></p><p>The safety of immunization with live or live-attenuated vaccines following OCREVUS therapy has not been studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion <em>[see 5.1 </em><em>Pharmacodynamic Properties</em><em>]</em>.</p><p><em>&nbsp;</em></p><p><em>Vaccination of Infants Born to Mothers Treated with OCREVUS During Pregnancy</em></p><p>In infants of mothers exposed to OCREVUS during pregnancy, do not administer live or live-attenuated vaccines before confirming the recovery of B-cell counts as measured by CD19<sup>+</sup> B-cells. &nbsp;Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines.&nbsp;</p><p>You may administer non-live vaccines, as indicated, prior to recovery from B-cell depletion, but should consider assessing vaccine immune responses, including consultation with a qualified specialist, to assess whether a protective immune response was mounted <em>[see 4.6 </em><em>Fertility, pregnancy and lactation].</em></p><p><em>&nbsp;</em></p><p><strong>Reduction in Immunoglobulins</strong></p><p>As expected with any B-cell depleting therapy, decreased immunoglobulin levels are observed with OCREVUS treatment. The pooled data of OCREVUS clinical studies (RMS and PPMS) and their open-label extensions (up to approximately 7 years of exposure) have shown an association between decreased levels of immunoglobulin G (IgG&lt;LLN) and increased rates of serious infections. Monitor the levels of quantitative serum immunoglobulins during OCREVUS treatment and after discontinuation of treatment, until B-cell repletion, and especially in the setting of recurrent serious infections. Consider discontinuing OCREVUS therapy in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins <em>[see 4.8 Undesirable effects]</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Malignancies</strong></p><p>An increased risk of malignancy with OCREVUS may exist.&nbsp; In controlled trials, malignancies, including breast cancer, occurred more frequently in OCREVUS-treated patients. Breast cancer occurred in 6 of 781 females treated with OCREVUS and none of 668 females treated with REBIF or placebo. Patients should follow standard breast cancer screening guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Immunosuppressive or Immune-Modulating Therapies<em> </em></strong></p><p>The concomitant use of OCREVUS and other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids, is expected to increase the risk of immunosuppression.&nbsp; Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with OCREVUS. When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS <em>[see 4.4 Special warnings and precautions for use]. </em></p><p><strong>&nbsp;</strong></p><p><strong>Vaccinations</strong></p><p>A Phase 3b randomized, open-label study examined the concomitant use of OCREVUS and several non-live vaccines in adults 18-55 years of age with relapsing forms of MS (68 subjects undergoing treatment with OCREVUS at the time of vaccination and 34 subjects not undergoing treatment with OCREVUS at the time of vaccination). &nbsp;Concomitant exposure to OCREVUS attenuated antibody responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide, pneumococcal conjugate vaccines, and seasonal inactivated influenza vaccines. &nbsp;The impact of the observed attenuation on vaccine effectiveness in this patient population is unknown. &nbsp;The safety and effectiveness of live or live-attenuated vaccines administered concomitantly with OCREVUS have not been assessed <em>[see 4.4 Special warnings and precautions for use]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p><u>Pregnancy Exposure Registry </u></p><p>There is a pregnancy exposure registry that monitors pregnancy and fetal/neonatal/infant outcomes in women exposed to OCREVUS during pregnancy.</p><p><u>Risk Summary</u></p><p>OCREVUS is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier.&nbsp; There are no adequate data on the developmental risk associated with use of OCREVUS in pregnant women.&nbsp; However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. &nbsp;B-cell levels in infants following maternal exposure to OCREVUS have not been studied in clinical trials.&nbsp; The potential duration of B-cell depletion in such infants, and the impact of B-cell depletion on vaccine safety and effectiveness, is unknown <em>[see 4.4 Special warnings and precautions for use]</em>.</p><p>Following administration of ocrelizumab to pregnant monkeys at doses similar to or greater than those used clinically, increased perinatal mortality, depletion of B-cell populations, renal, bone marrow, and testicular toxicity were observed in the offspring in the absence of maternal toxicity <em>[see Data]</em>.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.&nbsp; The background risk of major birth defects and miscarriage for the indicated population is unknown.</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>Following intravenous administration of OCREVUS to monkeys during organogenesis (loading doses of 15 or 75 mg/kg on gestation days 20, 21, and 22, followed by weekly doses of 20 or 100 mg/kg), depletion of B-lymphocytes in lymphoid tissue (spleen and lymph nodes) was observed in fetuses at both doses.&nbsp;</p><p>Intravenous administration of OCREVUS (three daily loading doses of 15 or 75 mg/kg, followed by weekly doses of 20 or 100 mg/kg) to pregnant monkeys throughout the period of organogenesis and continuing through the neonatal period resulted in perinatal deaths (some associated with bacterial infections), renal toxicity (glomerulopathy and inflammation), lymphoid follicle formation in the bone marrow, and severe decreases in circulating B-lymphocytes in neonates.&nbsp; The cause of the neonatal deaths is uncertain; however, both affected neonates were found to have bacterial infections. Reduced testicular weight was observed in neonates at the high dose.</p><p>A no-effect dose for adverse developmental effects was not identified; the doses tested in monkey are 2 and 10 times the recommended human dose of 600 mg, on a mg/kg basis.</p><p>&nbsp;</p><p>Lactation</p><p><u>Risk Summary</u></p><p>There are no data on the presence of ocrelizumab in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. &nbsp;Ocrelizumab was excreted in the milk of ocrelizumab-treated monkeys. &nbsp;Human IgG is excreted in human milk, and the potential for absorption of ocrelizumab to lead to B-cell depletion in the infant is unknown. &nbsp;The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for OCREVUS and any potential adverse effects on the breastfed infant from OCREVUS or from the underlying maternal condition.</p><p>&nbsp;</p><p>Females and Males of Reproductive Potential</p><p><u>Contraception </u></p><p>Women of childbearing potential should use effective contraception while receiving OCREVUS and for 6 months after the last infusion of OCREVUS <em>[see 5.1 </em><em>Pharmacodynamic Properties</em><em>]</em>.</p><p>&nbsp;</p><p>Pediatric Use&nbsp;</p><p>Safety and effectiveness of OCREVUS in pediatric patients have not been established.</p><p>&nbsp;</p><p>Geriatric Use</p><p>Clinical studies of OCREVUS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ocrevus has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion Reactions <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in Immunoglobulins <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignancies <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&nbsp;</p><p>Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>The safety of OCREVUS has been evaluated in 1311 patients across MS clinical studies, which included 825&nbsp;patients in active-controlled clinical trials in patients with relapsing forms of MS (RMS) and 486 patients in a placebo-controlled study in patients with primary progressive MS (PPMS).&nbsp;</p><p><u>Adverse Reactions in Patients with Relapsing Forms of MS </u></p><p>In active-controlled clinical trials (Study 1 and Study 2), 825 patients with RMS received OCREVUS 600 mg intravenously every 24 weeks (initial treatment was given as two separate 300 mg infusions at Weeks 0 and 2) <em>[see </em><em>5.1 Pharmacodynamic properties, Clinical efficacy and safety</em><em>]. </em>&nbsp;The overall exposure in the 96-week controlled treatment periods was 1448 patient-years.</p><p>The most common adverse reactions in RMS trials (incidence &ge; 10%) were upper respiratory tract infections and infusion reactions. &nbsp;Table 2 summarizes the adverse reactions that occurred in RMS trials (Study 1 and Study 2).</p><p>&nbsp;</p><p><strong>Table 2&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions in Adult Patients with RMS with an Incidence of at least 5% for OCREVUS and Higher than REBIF</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td rowspan="2"><p><strong>Adverse Reactions</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Studies 1 and 2</strong></p></td></tr><tr><td><p><strong>OCREVUS</strong></p><p><strong>600 mg IV</strong></p><p><strong>Every 24 Weeks<sup>1</sup></strong></p><p><strong>(n=825)</strong></p><p><strong>%</strong></p></td><td><p><strong>REBIF</strong></p><p><strong>44 mcg SQ</strong></p><p><strong>3 Times per Week</strong></p><p><strong>(n=826)</strong></p><p><strong>%</strong></p></td></tr></thead><tbody><tr><td><p>Upper respiratory tract infections</p></td><td><p>40</p></td><td><p>33</p></td></tr><tr><td><p>Infusion reactions</p></td><td><p>34</p></td><td><p>10</p></td></tr><tr><td><p>Depression</p></td><td><p>8</p></td><td><p>7</p></td></tr><tr><td><p>Lower respiratory tract infections</p></td><td><p>8</p></td><td><p>5</p></td></tr><tr><td><p>Back pain</p></td><td><p>6</p></td><td><p>5</p></td></tr><tr><td><p>Herpes virus- associated infections</p></td><td><p>6</p></td><td><p>4</p></td></tr><tr><td><p>Pain in extremity</p></td><td><p>5</p></td><td><p>4</p></td></tr></tbody></table><p><sup>1 </sup>The first dose was given as two separate 300 mg infusions at Weeks 0 and 2.</p><p><u>&nbsp;</u></p><p><u>Adverse Reactions in Patients with Primary Progressive MS</u></p><p>In a placebo-controlled clinical trial (Study 3), a total of 486 patients with PPMS received one course of OCREVUS (600 mg of OCREVUS administered as two 300 mg infusions two weeks apart) given intravenously every 24 weeks and 239 patients received placebo intravenously <em>[see </em><em>5.1 Pharmacodynamic properties, Clinical efficacy and safety</em><em>].</em> &nbsp;The overall exposure in the controlled treatment period was 1416 patient-years, with median treatment duration of 3 years.</p><p>The most common adverse reactions in the PPMS trial (incidence &ge; 10%) were upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections. Table 3 summarizes the<br />adverse reactions that occurred in the PPMS trial (Study 3).</p><p><strong>&nbsp;</strong></p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions in Adult Patients with PPMS with an Incidence of at least 5% for OCREVUS and Higher than Placebo </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td rowspan="2"><p><strong>Adverse Reactions</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Study 3</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OCREVUS</strong></p><p><strong>600 mg IV Every 24 Weeks<sup>1</sup></strong></p><p><strong>(n=486)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>(n=239)</strong></p><p><strong>%</strong></p></td></tr></thead><tbody><tr><td><p>Upper respiratory tract infections</p></td><td><p>49</p></td><td><p>43</p></td></tr><tr><td><p>Infusion reactions</p></td><td><p>40</p></td><td><p>26</p></td></tr><tr><td><p>Skin infections</p></td><td><p>14</p></td><td><p>11</p></td></tr><tr><td><p>Lower respiratory tract infections</p></td><td><p>10</p></td><td><p>9</p></td></tr><tr><td><p>Cough</p></td><td><p>7</p></td><td><p>3</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>6</p></td><td><p>5</p></td></tr><tr><td><p>Edema peripheral</p></td><td><p>6</p></td><td><p>5</p></td></tr><tr><td><p>Herpes virus associated infections</p></td><td><p>5</p></td><td><p>4</p></td></tr></tbody></table><p><sup>1 </sup>One dose of OCREVUS (600 mg administered as two 300 mg infusions two weeks apart)</p><p><u>&nbsp;</u></p><p><u>Adverse Reactions in Patients who Received 2-hour Infusions</u></p><p>Study 4 was designed to characterize the safety profile of OCREVUS infusions administered over 2 hours in patients with Relapsing-Remitting Multiple Sclerosis who did not experience a serious infusion reaction with any previous OCREVUS infusion. In this study, the incidence, intensity, and types of symptoms of infusion reactions were consistent with those of infusions administered over 3.5 hours <em>[see </em><em>5.1 </em><em>Pharmacodynamic Properties</em><em>]</em>.</p><p>&nbsp;</p><p><u>Laboratory Abnormalities</u></p><p><em>Decreased Immunoglobulins</em></p><p>OCREVUS decreased total immunoglobulins with the greatest decline seen in IgM levels; however, a decrease in IgG levels was associated with an increased rate of serious infections.</p><p>In the active-controlled (RMS) trials (Study 1 and Study 2), the proportion of patients at baseline reporting IgG, IgA, and IgM &nbsp;below the lower limit of normal (LLN) in OCREVUS-treated patients was 0.5%, 1.5%, and 0.1%, respectively. &nbsp;Following treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA, and IgM below the LLN at 96 weeks was 1.5%, 2.4%, and 16.5%, respectively.</p><p>In the placebo-controlled (PPMS) trial (Study 3), the proportion of patients at baseline reporting IgG, IgA, and IgM below the LLN in OCREVUS-treated patients was 0.0%, 0.2%, and 0.2%, respectively.&nbsp; Following treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA, and IgM below the LLN at 120 weeks was 1.1%, 0.5%, and 15.5%, respectively.</p><p>The pooled data of OCREVUS clinical studies (RMS and PPMS) and their open-label extensions (up to approximately 7 years of exposure) have shown an association between decreased levels of IgG and increased rates of serious infections. The type, severity, latency, duration, and outcome of serious infections observed during episodes of immunoglobulins below LLN were consistent with the overall serious infections observed in patients treated with OCREVUS.</p><p><em>&nbsp;</em></p><p><em>Decreased Neutrophil Levels</em></p><p>In the PPMS clinical trial (Study 3), decreased neutrophil counts occurred in 13% of OCREVUS-treated patients compared to 10% in placebo patients.&nbsp; The majority of the decreased neutrophil counts were only observed once for a given patient treated with OCREVUS and were between LLN - 1.5 x 10<sup>9</sup>/L and 1.0 x 10<sup>9</sup>/L.&nbsp; Overall, 1% of the patients in the OCREVUS group had neutrophil counts less than 1.0 x 10<sup>9</sup>/L and these were not associated with an infection.</p><p>&nbsp;</p><p>Immunogenicity</p><p>As with all therapeutic proteins, there is potential for immunogenicity. &nbsp;Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used. &nbsp;Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication, and the underlying disease. &nbsp;Therefore, comparison of the incidence of antibodies to OCREVUS with the incidence of antibodies to other products may be misleading.</p><p>Patients in MS trials (Study 1, Study 2, and Study 3) were tested at multiple time points (baseline and every 6 months post-treatment for the duration of the trial) for anti-drug antibodies (ADAs).&nbsp; Out of 1311 patients treated with OCREVUS, 12 (~1%) tested positive for ADAs, of which 2 patients tested positive for neutralizing antibodies. &nbsp;These data are not adequate to assess the impact of ADAs on the safety and efficacy of OCREVUS.</p><p><strong>&nbsp;</strong></p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during postapproval use of OCREVUS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp;</p><p>Serious herpes infections have been identified during postapproval use of OCREVUS <em>[see 4.4 Special warnings and precautions for use].</em></p><p><em>&nbsp;</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:478px"><tbody><tr><td style="vertical-align:top; width:475px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; SFDA call center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:476px"><tbody><tr><td style="vertical-align:top; width:473px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited clinical trial experience with doses higher than the approved intravenous dose of Ocrevus. The highest dose tested to date in MS patients is 2000 mg, administered as two 1000 mg intravenous infusions separated by 2 weeks (Phase II dose finding study in RRMS).&nbsp; The adverse drug reactions were consistent with the safety profile for Ocrevus in the pivotal clinical studies.</p><p>&nbsp;</p><p>Please refer to section 4.8 for information about the Systemic Inflammatory Response Syndrome (SIRS) that occurred in a patient treated with&nbsp; Ocrevus 2000 mg.</p><p>&nbsp;</p><p>There is no specific antidote in the event of an overdose; interrupt the infusion immediately and observe the patient for IRRs (see section 4.4).&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: selective immunosuppressants group, ATC code: L04AA36.</p><p>&nbsp;</p><p>Mechanism of Action</p><p>The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and&nbsp; complement-mediated lysis.</p><p>&nbsp;</p><p>Pharmacodynamics</p><p>For B-cell counts, assays for CD19<sup>+</sup> B-cells are used because the presence of OCREVUS interferes with the CD20 assay.&nbsp; Treatment with OCREVUS reduces CD19<sup>+</sup> B-cell counts in blood by 14 days after infusion.&nbsp; In clinical studies, B-cell counts rose to above the lower limit of normal (LLN) or above baseline counts between infusions of OCREVUS at least one time in 0.3% to 4.1% of patients.&nbsp; In a clinical study of 51 patients, the median time for B-cell counts to return to either baseline or LLN was 72&nbsp;weeks (range 27-175 weeks) after the last OCREVUS infusion.&nbsp; Within 2.5 years after the last infusion, B-cell counts rose to either baseline or LLN in 90% of patients.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Relapsing Forms of Multiple Sclerosis (RMS)</p><p>The efficacy of OCREVUS was demonstrated in two randomized, double-blind, double-dummy, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks (Study1 and Study 2).&nbsp; The dose of OCREVUS was 600 mg every 24 weeks (initial treatment was given as two 300 mg IV infusions administered 2 weeks apart, and subsequent doses were administered as a single 600&nbsp;mg IV infusion) and placebo subcutaneous injections were given 3 times per week. &nbsp;The dose of REBIF, the active comparator, was 44 mcg given as subcutaneous injections 3 times per week and placebo IV infusions were given every 24 weeks. &nbsp;Both studies included patients who had experienced at least one relapse within the prior year, or two relapses within the prior two years, and had an Expanded Disability Status Scale (EDSS) score from 0 to 5.5. Patients with primary progressive forms of multiple sclerosis (MS) were excluded.&nbsp; Neurological evaluations were performed every 12 weeks and at the time of a suspected relapse. &nbsp;Brain MRIs were performed at baseline and at Weeks 24, 48, and 96. &nbsp;&nbsp;</p><p>The primary outcome of both Study 1 and Study 2 was the annualized relapse rate (ARR). &nbsp;Additional outcome measures included the proportion of patients with confirmed disability progression, the mean number of MRI T1 gadolinium (Gd)-enhancing lesions at Weeks 24, 48, and 96, and new or enlarging MRI T2 hyperintense lesions. &nbsp;Progression of disability was defined as an increase of 1 point or more from the baseline EDSS score&nbsp; attributable to MS when the baseline EDSS score was 5.5 or less, or 0.5 points or more when the baseline EDSS score was above 5.5. &nbsp;Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit 12 weeks after the initial documentation of neurological worsening. &nbsp;The primary population for analysis of confirmed disability progression was the pooled population from Studies 1 and 2.</p><p>In Study 1, 410 patients were randomized to OCREVUS and 411 to REBIF; 11% of OCREVUS-treated and 17% of REBIF-treated patients did not complete the 96-week double-blind treatment period. &nbsp;The baseline demographic and disease characteristics were balanced between the two treatment groups. &nbsp;At baseline, the mean age of patients was 37 years; 66% were female. &nbsp;The mean time from MS diagnosis to randomization was 3.8 years, the mean number of relapses in the previous year was 1.3, and the mean EDSS score was 2.8; &nbsp;74% of patients had not been treated with a non-steroid therapy for MS in the 2 years prior to the study. At baseline, 40% of patients had one or more T1 Gd-enhancing lesions (mean 1.8). &nbsp;</p><p>&nbsp;</p><p>In Study 2, 417 patients were randomized to OCREVUS and 418 to REBIF; 14% of OCREVUS-treated and 23% of REBIF-treated patients did not complete the 96-week double-blind treatment period. &nbsp;The baseline demographic and disease characteristics were balanced between the two treatment groups. At baseline, the mean age of patients was 37 years; 66% were female. &nbsp;The mean time from MS diagnosis to randomization was 4.1 years, the mean number of relapses in the previous year was 1.3, and the mean EDSS score was 2.8;&nbsp; 74% of patients had not been treated with a non-steroid therapy for MS in the 2 years prior to the study.&nbsp; At baseline, 40% of OCREVUS-treated patients had one or more T1 Gd-enhancing lesions (mean 1.9).</p><p>In Study 1 and Study 2, OCREVUS significantly lowered the annualized relapse rate and the proportion of patients with disability progression confirmed at 12 weeks after onset compared to REBIF. &nbsp;Results for Study 1 and Study 2 are presented in Table 4 and Figure 1.&nbsp;</p><p><strong>&nbsp;</strong></p><p><img src="data:image/png;base64,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" alt="" width="761" height="529" vspace="0" hspace="0" border="0" style="width:761px;height:529px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="748" height="454" vspace="0" hspace="0" border="0" style="width:748px;height:454px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>In exploratory subgroup analyses of Study 1 and Study 2, the effect of OCREVUS on annualized relapse rate and disability progression was similar in male and female patients.</p><p>&nbsp;</p><p>Primary Progressive Multiple Sclerosis (PPMS)</p><p>Study 3 was a randomized, double-blind, placebo-controlled clinical trial in patients with PPMS.&nbsp; Patients were randomized 2:1 to receive either OCREVUS 600 mg or placebo as two 300 mg intravenous infusions 2 weeks apart every 24 weeks for at least 120 weeks.&nbsp; Selection criteria required a baseline EDSS of 3 to 6.5 and a score of 2 or greater for the EDSS pyramidal functional system due to lower extremity findings. &nbsp;Neurological assessments were conducted every 12 weeks. &nbsp;An MRI scan was obtained at baseline and at Weeks 24, 48, and 120. &nbsp;&nbsp;</p><p>In Study 3, the primary outcome was the time to onset of disability progression attributable to MS confirmed to be present at the next neurological assessment at least 12 weeks later. &nbsp;Disability progression occurred when the EDSS score increased by 1 point or more from the baseline EDSS if the baseline EDSS was 5.5 points or less, or by 0.5 points or more if the baseline EDSS was more than 5.5 points.&nbsp; In Study 3, confirmed disability progression also was deemed to have occurred if patients who had onset of disability progression discontinued participation in the study before the next assessment. Additional outcome measures included timed 25-foot walk, and percentage change in T2 hyperintense lesion volume.</p><p>&nbsp;</p><p>Study 3 randomized 488 patients to OCREVUS and 244 to placebo; 21% of OCREVUS-treated patients and 34% of placebo-treated patients did not complete the trial.&nbsp; The baseline demographic and disease characteristics were balanced between the two treatment groups. &nbsp;At baseline, the mean age of patients was 45; &nbsp;49% were female. The mean time since symptom onset was 6.7 years, the mean EDSS score was 4.7, and 26% had one or more T1 Gd-enhancing lesions at baseline; 88% of patients had not been treated previously with&nbsp; a non-steroid treatment for MS. &nbsp;The time to onset of disability progression confirmed at 12 weeks after onset was significantly longer for OCREVUS-treated patients than for placebo-treated patients (see Figure 2).&nbsp; Results for Study 3 are presented in Table 5 and Figure 2.</p><p><strong>&nbsp;<img src="data:image/png;base64,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" alt="" width="726" height="443" vspace="0" hspace="0" border="0" style="width:726px;height:443px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="777" height="583" vspace="0" hspace="0" border="0" style="width:777px;height:583px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>In the overall population in Study 3, the proportion of patients with 20 percent worsening of the timed 25-foot walk confirmed at 12 weeks was 49% &nbsp;in OCREVUS-treated patients compared to 59% in placebo-treated patients (25% risk reduction).</p><p>In exploratory subgroup analyses of Study 3, the proportion of female patients with disability progression confirmed at 12 weeks after onset was similar in OCREVUS-treated patients and placebo-treated patients (approximately 36% in each group).&nbsp; In male patients, the proportion of patients with disability progression confirmed at 12 weeks after onset was approximately 30% in OCREVUS-treated patients and 43% in placebo-treated patients.&nbsp; Clinical and MRI endpoints that generally favored OCREVUS numerically in the overall population, and that showed similar trends in both male and female patients, included annualized relapse rate, change in T2 lesion volume, and number of new or enlarging T2 lesions.</p><p>&nbsp;</p><p><strong>Safety Study of 2-Hour Infusions</strong></p><p>The safety of the 2-hour OCREVUS infusion was evaluated in Study 4 (NCT03085810), a prospective, multicenter, randomized, double-blind, controlled, parallel arm substudy in patients with Relapsing-Remitting Multiple Sclerosis who were na&iuml;ve to other non-steroid therapies for MS and did not experience a serious infusion reaction with any previous OCREVUS infusion.&nbsp; The first dose of OCREVUS was administered as two 300 mg infusions (600 mg total) separated by 14 days. After enrollment in the substudy, patients were randomized in a 1:1 ratio to receive infusions over approximately 3.5-hours or 2-hours, after appropriate premedication <em>[</em><em>see 4.2 Posology and method of administration]</em>, every 24 weeks. The randomization was stratified by region and the dose at which patients were first randomized.</p><p>The primary endpoint of the substudy was the proportion of patients with infusion reactions occurring during or within 24 hours following the first randomized infusion of OCREVUS. The primary analysis was performed when 580 patients were randomized, at which time 469/579 (81%) of the treated patients had received only a single randomized infusion of OCREVUS. The proportions of patients with infusion reactions occurring during or within 24 hours following the first randomized infusion in this substudy were similar between the 2-hour and 3.5-hour infusion groups (24.4% versus 23.3%, respectively). Overall, in all randomized doses, 27.1% of the patients in the 2-hour infusion group and 25.0% of the patients in the 3.5-hour infusion group reported mild or moderate infusion reactions; two infusion reactions were severe in intensity, with one severe infusion reaction (0.3%) reported in one patient in each group in this substudy <em>[see 4.4 Special warnings and precautions for use]</em>. There were no life-threatening, fatal, or serious infusion reactions in this substudy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics (PK) of OCREVUS in MS clinical studies fit a two compartment model with time‑dependent clearance. &nbsp;The overall exposure at the steady-state (AUC over the 24 week dosing intervals) of OCREVUS was 3,510 mcg/mL per day.&nbsp; In clinical studies in MS patients, maintenance doses of ocrelizumab were either 600&nbsp;mg every 6 months (RMS patients) or two 300 mg infusions separated by 14 days every 6 months (PPMS patients). The mean maximum concentration was 212 mcg/mL in patients with RMS (600 mg infusion over 3.5 hours) and 141 mcg/mL in patients with PPMS (two 300 mg infusions over 2.5 hours administered within two weeks). &nbsp;The mean maximum peak concentrations (Cmax)&nbsp;of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS) observed after the 3.5-hour infusion and 2-hour infusion were 202 &plusmn; 42 (mean &plusmn; SD) and 200 &plusmn; 46 mcg/mL, respectively, compared to the previously reported C<sub>max</sub> of 212 mcg/mL. The pharmacokinetics of ocrelizumab was essentially linear and dose proportional between 400 mg and 2000 mg.</p><p><u>Distribution </u></p><p>The population PK estimate of the central volume of distribution was 2.78 L. Peripheral volume and inter-compartment clearance were estimated at 2.68 L and 0.29 L/day, respectively.</p><p><u>Elimination</u></p><p>Constant clearance was estimated at 0.17 L/day, and initial time-dependent clearance at 0.05 L/day, which declined with a half-life of 33 weeks. The terminal elimination half-life was 26 days.</p><p><u>Metabolism</u></p><p>The metabolism of OCREVUS has not been directly studied because antibodies are cleared principally by catabolism.</p><p><u>Specific Populations</u></p><p><em>Renal impairment</em></p><p>Patients with mild renal impairment were included in clinical trials. No significant change in the pharmacokinetics of OCREVUS was observed in those patients.</p><p><em>Hepatic impairment</em></p><p>Patients with mild hepatic impairment were included in clinical trials. No significant change in the pharmacokinetics &nbsp;of OCREVUS &nbsp;was observed in those patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>No carcinogenicity studies have been performed to assess the carcinogenic potential of OCREVUS.</p><p>No studies have been performed to assess the mutagenic potential of OCREVUS. &nbsp;As an antibody, OCREVUS is not expected to interact directly with DNA.</p><p>No effects on reproductive organs were observed in male monkeys administered ocrelizumab by intravenous injection (three loading doses of 15 or 75 mg/kg, followed by weekly doses of 20 or 100 mg/kg) for 8 weeks.&nbsp; There were also no effects on estrus cycle in female monkeys administered ocrelizumab over three menstrual cycles using the same dosing regimen.&nbsp; The doses tested in monkey are 2 and 10 times the recommended human dose of 600 mg, on a mg/kg basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Acetate Trihydrate</p><p>Glacial Acetic Acid</p><p>Trehalose Dihydrate</p><p>Polysorbate 20</p><p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No incompatibilities between Ocrevus and polyvinyl chloride (PVC) or polyolefin (PO) bags and intravenous&nbsp; administration sets have been observed.</p><p>&nbsp;</p><p>Do not use diluents other than the one detailed in section 6.6 to dilute Ocrevus since its use has not been tested.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

24 months


Diluted solution for intravenous infusion 

Prior to the start of the intravenous infusion, the content of the infusion bag should be at room temperature.
Use the prepared infusion solution immediately.  If not used immediately, store up to 24 hours in the refrigerator at 2°C to 8°C (36°F to 46°F) and 8 hours at room temperature up to 25°C (77°F), which includes infusion time.  In the event an intravenous infusion cannot be completed the same day, discard the remaining solution. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze or shake.</p><p>Keep the vials in the outer carton in order to protect from light.&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 mL concentrate in a glass vial.&nbsp; Pack size of 1 or 2 vials.&nbsp; Not all pack sizes may be marketed.&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preparation and Storage of the Dilute Solution for Infusion</p><p><u>Preparation</u></p><p>OCREVUS must be prepared by a healthcare professional using aseptic technique. A sterile needle and syringe should be used to prepare the diluted infusion solution.</p><p>Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter.&nbsp; Do not shake.</p><p>Withdraw intended dose and further dilute into an infusion bag containing 0.9% Sodium Chloride Injection, to a final drug concentration of approximately 1.2 mg/mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw 10 mL (300 mg) of OCREVUS and inject into 250 mL</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw 20 mL (600 mg) of OCREVUS and inject into 500 mL</p><p>Do not use other diluents to dilute OCREVUS since their use has not been tested.&nbsp; The product contains no preservative and is intended for single use only.</p><p><u>Administration</u></p><p>Administer the diluted infusion solution through a dedicated line using an infusion set with a 0.2 or 0.22 micron in-line filter.</p><p><u>Disposal </u></p><p><em>Disposal of unused/expired medicines</em></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124, 
CH-4070 Basel, 
Switzerland.
8.	MARKETING AUTHORISATION NUMBER(S) 

288-24-17


9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21st November 2018


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 March 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>